Management Plan for Opioid Use Disorder
Clinicians should offer or arrange medication-assisted treatment with buprenorphine or methadone combined with behavioral therapies for patients with opioid use disorder, as this represents the evidence-based standard of care that reduces mortality and morbidity. 1
Initial Assessment and Diagnosis
When you suspect opioid use disorder based on patient concerns, behaviors, prescription drug monitoring program data, or urine drug testing results, directly discuss your concerns with the patient. Assess for opioid use disorder using DSM-5 criteria, which requires at least 2 of the defined criteria occurring within a year indicating a problematic pattern of opioid use leading to clinically significant impairment or distress 1. If you're unable to perform this assessment yourself, arrange for a substance use disorder treatment specialist to evaluate the patient.
First-Line Treatment: Medication-Assisted Treatment
Medication Selection
For most patients, initiate either buprenorphine or methadone as first-line treatment 1, 2. Recent evidence from 2024 demonstrates that methadone and buprenorphine are similarly effective in reducing opioid use and adverse events, making both preferred first-line options 2. This represents an important update from earlier guidance that prioritized one over the other.
Buprenorphine advantages:
- Can be prescribed in office-based settings by physicians with a DEA waiver (requires 8-hour training course) 1
- Lower risk of respiratory depression due to partial agonist properties and ceiling effect 3
- Safer if patient uses additional opioids after discharge 3
- Fewer drug-drug interactions 4
- Does not require daily clinic visits
Methadone advantages:
- Highest treatment retention rates across studies 4
- Long half-life ameliorates withdrawal cycles 5
- May be more effective for severe opioid use disorder
Critical caveat: Methadone requires careful dosing and monitoring in patients with hepatic, renal, or cardiovascular disease, and federal regulations restrict access for patients under 18 years 5, 4.
Alternative Medication Options
Naltrexone (oral or long-acting injectable) can be used as medication-assisted treatment in non-pregnant adults, particularly for highly motivated patients 1. However, naltrexone has significant limitations:
- Requires complete opioid abstinence before initiation (creates barrier to treatment)
- Blocks opioid effects but requires adherence to daily oral therapy or monthly injections
- Less robust evidence for efficacy compared to opioid agonist therapy 1
Slow-release oral morphine is recommended as a second-line option when first-line treatments are not suitable 2.
Behavioral Therapies
Combine medication with behavioral therapies, as studies demonstrate this combination reduces opioid misuse, increases retention during maintenance therapy, and improves compliance 1. However, psychosocial interventions should be offered as adjunctive treatment but not made mandatory 2. The medication itself is the critical component that reduces mortality.
Cognitive behavioral therapy (CBT) is particularly effective and should be incorporated when available 1.
Special Populations
Pregnant Women
Offer medication-assisted therapy with buprenorphine (without naloxone) or methadone, as both have been associated with improved maternal outcomes 1, 6. Do not use naltrexone in pregnancy.
Emergency Department Presentations
For opioid withdrawal in the ED, treat with buprenorphine or methadone as more effective options compared with non-opioid strategies (such as clonidine and antiemetics) 3. When possible, preferentially use buprenorphine rather than methadone in the ED setting 3.
Initiation of buprenorphine in the ED increases rates of outpatient treatment linkage and decreases drug use compared to standard referral 7.
Adolescents
Offer medication-assisted treatment to adolescents and young adults with severe opioid use disorder. Buprenorphine is FDA-approved for patients 16 years and older 5. The rate of spontaneous remission is low, making treatment essential.
Overdose Prevention
Offer naloxone for overdose prevention to all patients with opioid use disorder 1. Naloxone reverses opioid-induced respiratory depression and can be life-saving. Ensure patients and their families have access to naloxone and know how to use it.
Critical Management Pitfalls to Avoid
Do not dismiss patients from your practice because of substance use disorder - this adversely affects patient safety and represents patient abandonment 6. Identification of opioid use disorder is an opportunity to initiate life-saving interventions.
Do not use withdrawal management as a standalone intervention - this approach is associated with poor outcomes 2. Patients require ongoing medication-assisted treatment.
Do not require patients to "fail" other therapies before offering medication-assisted treatment - this delays life-saving treatment 8.
Avoid co-prescribing benzodiazepines with opioids whenever possible due to increased risk of fatal respiratory depression 1. If both are prescribed, taper opioids first as benzodiazepine withdrawal carries greater risks including seizures and delirium tremens 1.
Treatment Coordination and Follow-Up
If you cannot provide treatment yourself, arrange for patients to receive care from:
- Office-based buprenorphine or naltrexone treatment provider
- Opioid treatment program certified by SAMHSA for supervised medication-assisted treatment 1
Assist patients in finding qualified treatment providers and arrange direct linkage to ongoing treatment 7. Ensure coordination between primary care, addiction specialists, and mental health professionals managing the patient 1.
For physicians in communities without sufficient treatment capacity, strongly consider obtaining a buprenorphine waiver to expand access to treatment 1. No waiver is needed to prescribe naltrexone.
Concurrent Pain Management
For patients with co-occurring pain and opioid use disorder, continue medication-assisted treatment with buprenorphine or methadone while managing pain with:
- Multimodal, non-opioid therapy as first-line
- Short-acting opioid analgesics in addition to buprenorphine or methadone when needed for acute pain 9
- Consultation with pain specialists as needed 1
Buprenorphine provides some analgesic effect and should be continued during acute pain episodes or surgical procedures 9.